Ribonucleoside analogue
Treatment of infections caused by RNA viral pathogens, including SARS-CoV-2
Brite
Drug groups [BR:br08330]
Antiviral
DG03174 Anti-SARS-CoV-2 agent
D11943 Molnupiravir
Drug classes [BR:br08332]
Antiviral
DG03174 Anti-SARS-CoV-2 agent
D11943 Molnupiravir
Antimicrobials [BR:br08307]
Antivirals
Polyprotein cleavage inhibitor
SARS-CoV 3C protease inhibitor
D11943 Molnupiravir (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11943
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11943
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11943